AIM ImmunoTech Inc. Common Stock (NY:AIM)
All News about AIM ImmunoTech Inc. Common Stock


















Via Benzinga

AIM ImmunoTech Receives Positive FDA Response For Ampligen Trial In PCCD Patients
September 21, 2021
Via Benzinga
Exposures
Product Safety



Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free